Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia

被引:75
作者
Paz Garcia-Portilla, Maria [1 ]
Alejandra Saiz, Pilar [1 ]
Bousono, Manuel [1 ]
Teresa Bascaran, Maria [1 ]
Guzman-Quilo, Carlos
Bobes, Julio [1 ]
机构
[1] Univ Oviedo, Dept Psiquiatria, Ctr Invest Bioned Red Salud Mental, CIBERSAM, Oviedo, Spain
来源
REVISTA DE PSIQUIATRIA Y SALUD MENTAL | 2011年 / 4卷 / 01期
关键词
PSP; Social functioning; Personal functioning; Schizophrenia; Psychometric properties; DSM-IV; ACUTE SYMPTOMS; DETECT CHANGE; RELIABILITY; REMISSION; VALIDITY; ABILITY;
D O I
10.1016/j.rpsm.2010.11.003
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction: The main long-term therapeutic goals of schizophrenia should go beyond the symptoms and include the improvement of patients' psychosocial functioning and quality of life. The aim of this study was to validate the Personal and Social Performance (PSP) scale in Spanish outpatients with schizophrenia. Materials and methods: Naturalistic, 6-month follow-up, multicentre study. 244 patients and 76 controls were evaluated using the PSP, the Social and Occupational Functioning Assessment Scale (SOFAS), and the Clinical Global Impression - Severity (CGI-S) and Change (CGI-C) scales. Results: Internal reliability = 0.87. Test-retest reliability = 0.98. Construct validity = 1 component that explained 73.2% of the variance. Convergent validity: Pearson correlation coefficient between PSP and SOFAS = 0.95 (p < 0.0001), between PSP and CGI-S = -0.88 (p < 0.0001). Discriminant validity: the PSP discriminates between patients and controls [50.3 versus 91.9, p < 0.0001] and among patients with mild, moderate, and severe schizophrenia according to CGI-S scores [73 versus 56.6 versus 37.5, p < 0.0001]. Area under the curve = 0.986. A cut-off point of 79 on the PSP scale provided good sensitivity (94.3%) and specificity (96.1%) for identifying patients and controls according to their level of functioning. At month 6 significant improvements (p < 0.0001) were seen in PSP, SOFAS, and CGI-C scores. The PSP was sensitive to improvement; a score of very much improved in the CGI-C corresponds to a improvement of 34 points in the PSP. Conclusion: The Spanish PSP is a reliable, valid and sensitive instrument for measuring functioning in outpatients with schizophrenia. As a brief, clinician-rated instrument, the PSP scale seems to be appropriate for use in everyday clinical practice as a mean of identifying and monitoring changes in patient's functioning. (C) 2010 SEP y SEPB. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 28 条
[1]  
[Anonymous], Guidance for industry: patient reported outcome measures: use in medical product development to support labelling claims
[2]  
[Anonymous], 2005, REFL PAP REG GUID US
[3]   Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia [J].
Apiquian, Rogelio ;
Elena Ulloa, Rosa ;
Herrera-Estrella, Miguel ;
Moreno-Gomez, Araceli ;
Erosa, Sandra ;
Contreras, Veronica ;
Nicolini, Humberto .
SCHIZOPHRENIA RESEARCH, 2009, 112 (1-3) :181-186
[4]  
Bobes Julio, 2007, Dialogues Clin Neurosci, V9, P215
[5]   The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder [J].
Bouffard, R ;
Hechtman, L ;
Minde, K ;
Iaboni-Kassab, F .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (08) :546-554
[6]   Evolution of outcome measures in schizophrenia [J].
Burns, Tom .
BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 :S1-S6
[7]   Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies [J].
Emsley, Robin ;
Berwaerts, Joris ;
Eerdekens, Marielle ;
Kramer, Michelle ;
Lane, Rosanne ;
Lim, Pilar ;
Hough, David ;
Palumbo, Joseph .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (06) :343-356
[8]   World Federation of Societies of Biological Psychiatry (WFSBP) -: Guidelines for biological treatment of schizophrenia, part 1:: Acute treatment of schizophrenia [J].
Falkai, P ;
Wobrock, T ;
Lieberman, J ;
Glenthoj, B ;
Gattaz, WF ;
Möller, HJ .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2005, 6 (03) :132-191
[9]  
GOLDMAN HH, 1992, AM J PSYCHIAT, V149, P1148
[10]  
Guy W., 1976, EARLY CLIN DRUG EVAL